In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 61 to 70 of 293

TitleTypeExpected publication date
DCVax-L for treating glioblastoma [ID836]Technology appraisal guidanceTBC
Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]Technology appraisal guidance
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]Technology appraisal guidanceTBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]Technology appraisal guidance
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]Technology appraisal guidanceTBC
Deucravacitinib for treating active psoriatic arthritis [ID6561]Technology appraisal guidanceTBC
Deuruxolitinib for treating severe alopecia areata [ID6597]Technology appraisal guidance
Deutetrabenazine for treating tardive dyskinesia [ID6550]Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TSID10725]Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All